Zephyr AI is a high-growth healthcare technology company committed to radically reshaping precision medicine in oncology and cardiometabolic disease. Through partnerships and proprietary data, Zephyr AI is curating the world's most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support patients and providers and fuel ongoing research. At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and next-generation technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer and cardiometabolic disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/13/24 | $111,000,000 | Series A |
Eli Lilly and Company EPIQ Capital Group Jeff Skoll Revolution Growth | undisclosed |
| 10/21/24 | $60,000,000 | Growth |
Elda River Capital The Pritzker Organization | undisclosed |
